A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML
Public ClinicalTrials.gov record NCT01861002. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Study identification
- NCT ID
- NCT01861002
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Enrollment
- 15 participants
Conditions and interventions
Interventions
- Azacytidine Drug
- Cytarabine Drug
- Fludarabine Drug
- Intrathecal (IT) Cytarabine Drug
- Intrathecal Methotrexate (IT MTX) Drug
Drug
Eligibility (public fields only)
- Age range
- 1 Year to 21 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 21, 2013
- Primary completion
- Jul 27, 2014
- Completion
- Jul 27, 2014
- Last update posted
- Jun 8, 2021
2013 – 2014
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Childrens Hospital Los Angeles | Los Angeles | California | 90027 | — |
| UCSF School of Medicine | San Francisco | California | 94143-0106 | — |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | — |
| Children's Healthcare of Atlanta, Emory University | Atlanta | Georgia | 30322 | — |
| Johns Hopkins University | Baltimore | Maryland | 21287 | — |
| Dana Farber | Boston | Massachusetts | 02215 | — |
| C.S. Mott Children's Hospital | Ann Arbor | Michigan | 48109-0914 | — |
| Childrens Hospital & Clinics of Minnesota | Minneapolis | Minnesota | 55404-4597 | — |
| Children's Mercy Hospitals and Clinics | Kansas City | Missouri | 64108 | — |
| Children's Hospital New York-Presbyterian | New York | New York | 10032 | — |
| Levine Children's Hospital at Carolinas Medical Center | Charlotte | North Carolina | 28203 | — |
| Rainbow Babies & Children's Hospital | Cleveland | Ohio | 44106 | — |
| Nationwide Childrens Hospital | Columbus | Ohio | 43205 | — |
| Vanderbilt Children's Hospital | Nashville | Tennessee | 37232 | — |
| University of Texas at Southwestern | Dallas | Texas | 75235 | — |
| Cook Children's Medical Center | Fort Worth | Texas | 76104 | — |
| Primary Children's Medical Center | Salt Lake City | Utah | 84113 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
| Children's Hospital of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01861002, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 8, 2021 · Synced May 16, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01861002 live on ClinicalTrials.gov.